• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化的基线特征:来自澳大利亚特发性肺纤维化登记处的分析。

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

机构信息

Dept of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia

Faculty of Medicine, University of Sydney, Sydney, Australia.

出版信息

Eur Respir J. 2017 Feb 23;49(2). doi: 10.1183/13993003.01592-2016. Print 2017 Feb.

DOI:10.1183/13993003.01592-2016
PMID:28232409
Abstract

7The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25-63 out of 100 000, making large population studies difficult. Recently, the need for large longitudinal registries to study IPF has been recognised.The Australian IPF Registry (AIPFR) is a national registry collating comprehensive longitudinal data of IPF patients across Australia. We explored the characteristics of this IPF cohort and the effect of demographic and physiological parameters and specific management on mortality.Participants in the AIPFR (n=647, mean age 70.9±8.5 years, 67.7% male, median follow up 2 years, range 6 months-4.5 years) displayed a wide range of age, disease severity and co-morbidities that is not present in clinical trial cohorts. The cumulative mortality rate in year one, two, three and four was 5%, 24%, 37% and 44% respectively. Baseline lung function (forced vital capacity, diffusing capacity of the lung for carbon monoxide, composite physiological index) and GAP (gender, age, physiology) stage (hazard ratio 4.64, 95% CI 3.33-6.47, p<0.001) were strong predictors of mortality. Patients receiving anti-fibrotic medications had better survival (hazard ratio 0.56, 95% CI 0.34-0.92, p=0.022) than those not on anti-fibrotic medications, independent of underlying disease severity.The AIPFR provides important insights into the understanding of the natural history and clinical management of IPF.

摘要

7 特发性肺纤维化 (IPF) 的患病率估计为每 10 万人中有 1.25-63 人,这使得进行大规模人群研究变得困难。最近,人们认识到需要大型纵向登记处来研究特发性肺纤维化。澳大利亚特发性肺纤维化登记处 (AIPFR) 是一个全国性的登记处,汇集了澳大利亚各地特发性肺纤维化患者的全面纵向数据。我们探讨了这一特发性肺纤维化队列的特征,以及人口统计学和生理学参数以及特定管理对死亡率的影响。

AIPFR(n=647,平均年龄 70.9±8.5 岁,67.7%为男性,中位随访时间为 2 年,范围为 6 个月-4.5 年)的参与者表现出广泛的年龄、疾病严重程度和合并症,这在临床试验队列中并不存在。第一年、第二年、第三年和第四年的累积死亡率分别为 5%、24%、37%和 44%。基线肺功能(用力肺活量、一氧化碳弥散量、综合生理指数)和 GAP(性别、年龄、生理学)分期(危险比 4.64,95%CI 3.33-6.47,p<0.001)是死亡率的强有力预测因素。接受抗纤维化药物治疗的患者比未接受抗纤维化药物治疗的患者生存率更好(危险比 0.56,95%CI 0.34-0.92,p=0.022),这与潜在疾病严重程度无关。

AIPFR 为理解特发性肺纤维化的自然史和临床管理提供了重要的见解。

相似文献

1
Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.特发性肺纤维化的基线特征:来自澳大利亚特发性肺纤维化登记处的分析。
Eur Respir J. 2017 Feb 23;49(2). doi: 10.1183/13993003.01592-2016. Print 2017 Feb.
2
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.特发性肺纤维化合并轻度生理损害的疾病进展:来自澳大利亚特发性肺纤维化登记处的分析。
BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.
3
Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.特发性肺纤维化患者的基线特征和生存情况:瑞典特发性肺纤维化登记处的纵向分析。
Respir Res. 2021 Feb 5;22(1):40. doi: 10.1186/s12931-021-01634-x.
4
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者用力肺活量急性加重和下降与死亡率升高相关。
Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.
5
Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis.多次呼吸冲洗:一种用于特发性肺纤维化患者的新型且有前途的肺功能测试。
Respirology. 2018 Aug;23(8):764-770. doi: 10.1111/resp.13294. Epub 2018 Mar 24.
6
Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing.特发性肺纤维化的抗纤维化治疗资格取决于用于肺功能测试的预测方程。
Respirology. 2019 Oct;24(10):988-995. doi: 10.1111/resp.13540. Epub 2019 Mar 28.
7
EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.EMPIRE 注册研究,捷克部分:人口统计学、肺功能和高分辨率计算机断层扫描对特发性肺纤维化患者生存及临床病程的影响
Clin Respir J. 2018 Apr;12(4):1526-1535. doi: 10.1111/crj.12700. Epub 2017 Sep 26.
8
Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry.特发性肺纤维化患者的健康相关生活质量:来自澳大利亚特发性肺纤维化登记处的数据。
Respirology. 2017 Jul;22(5):950-956. doi: 10.1111/resp.12989. Epub 2017 Feb 6.
9
Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.特发性肺纤维化诊断后死亡或肺移植的预测因素:来自 IPF-PRO 登记处的见解。
Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
10
Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.特发性肺纤维化患者真实世界人群中的纵向临床结局:PROOF 登记研究。
Respir Res. 2019 Oct 24;20(1):231. doi: 10.1186/s12931-019-1182-z.

引用本文的文献

1
Clinical characteristics and all-cause mortality in female patients with idiopathic pulmonary fibrosis in Chinese population.中国人群中特发性肺纤维化女性患者的临床特征及全因死亡率
J Glob Health. 2025 Aug 29;15:04246. doi: 10.7189/jogh.15.04246.
2
Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases.间质性肺疾病的病理生理见解与临床管理策略
Biomol Ther (Seoul). 2025 Sep 1;33(5):785-803. doi: 10.4062/biomolther.2025.003. Epub 2025 Aug 14.
3
Sexual dimorphism of lung immune-regulatory units imprint biased pulmonary fibrosis.
肺免疫调节单位的性二态性导致偏向性肺纤维化。
Cell Mol Immunol. 2025 May 14. doi: 10.1038/s41423-025-01293-8.
4
Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.吡非尼酮和尼达尼布的上市后安全性问题:对来自美国食品药品监督管理局不良事件报告系统数据库和日本药品不良事件报告数据库的个体病例安全报告的分析
Front Pharmacol. 2025 Apr 28;16:1530697. doi: 10.3389/fphar.2025.1530697. eCollection 2025.
5
Treatable traits in interstitial lung disease: a narrative review.间质性肺疾病的可治疗特征:一篇叙述性综述
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251335774. doi: 10.1177/17534666251335774. Epub 2025 May 3.
6
Sex-specific aspects in a population of patients undergoing evaluation for interstitial lung disease with transbronchial cryobiopsy.经支气管冷冻活检评估间质性肺疾病患者群体中的性别特异性方面。
Sci Rep. 2025 Apr 5;15(1):11730. doi: 10.1038/s41598-025-94575-0.
7
The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis.合并症对特发性肺纤维化患者抗纤维化治疗中断的影响。
Pharmaceuticals (Basel). 2025 Mar 14;18(3):411. doi: 10.3390/ph18030411.
8
Comorbidities in the idiopathic pulmonary fibrosis and progressive pulmonary fibrosis trial population: a systematic review and meta-analysis.特发性肺纤维化和进行性肺纤维化试验人群中的合并症:一项系统评价和荟萃分析。
Eur Respir Rev. 2025 Mar 19;34(175). doi: 10.1183/16000617.0238-2024. Print 2025 Jan.
9
Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry.英国特发性肺纤维化:来自英国胸科学会英国特发性肺纤维化注册研究的结果
BMJ Open Respir Res. 2025 Feb 19;12(1):e002773. doi: 10.1136/bmjresp-2024-002773.
10
Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients.治疗前基质金属蛋白酶7可预测接受抗纤维化治疗患者的进行性特发性肺纤维化
Respirology. 2025 Jun;30(6):504-514. doi: 10.1111/resp.14894. Epub 2025 Feb 7.